A trial to learn if itraconazole and carbamazepine affect how AZD5462 moves throughout the bodies of healthy adults

This study is a very early stage of research, often called a 'Phase I' study. Its main purpose is to understand how a new medicine, which we'll call AZD5462, works in the human body. We're particularly interested in how other common medicines might affect it. Imagine AZD5462 as a new car. We want to see how this car performs on its own, but also if it drives differently when you fill it with a particular type of fuel (like itraconazole, used for fungal infections) or if you add a specific additive to the engine (like carbamazepine, used for epilepsy or nerve pain).

The reason this is important is because many people, especially those with long-term conditions like chronic heart failure, often take several different medicines at once. Sometimes, one medicine can change how another medicine works in the body. It might make it more effective, less effective, or even cause unwanted side effects. By understanding these interactions early on, researchers can make sure that new medicines like AZD5462 can be given safely and effectively in the future, especially to patients who might be taking other medications.

This study isn't directly testing AZD5462 as a treatment for heart failure yet. Instead, it's gathering crucial information about its basic behaviour in healthy people. This helps us ensure that when it eventually moves to studies with patients who have heart failure, we will have a clearer picture of how it might interact with the other medicines they are already taking. It's a key step in developing new, safe, and effective treatments.